Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
Biogen Adds Two More Biosimilars in $100M Deal with Samsung Bioepis | Frank Vinluan | 11/06/19 | Boston |
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop | Ben Fidler | 08/29/19 | Detroit Ann Arbor |
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More | Ben Fidler | 07/26/19 | National |
Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More | Frank Vinluan | 06/21/19 | National |
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms | Frank Vinluan | 04/19/18 | Indiana |
Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis | Frank Vinluan | 02/13/18 | Indiana |
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission | Frank Vinluan | 08/30/17 | Indiana |
Gilman Scores for Atlas Again as Bristol Buys Padlock for up to $600M | Ben Fidler | 03/23/16 | Boston |
Bird Rock Bio Nears Pivotal Trial of New Biologic Drug for RA | Bruce V. Bigelow | 03/16/16 | San Diego |